Estrella Immunopharma, Inc.
ESLAWNasdaq
$0.08
↓ -1.5%Jul 16 close · end-of-day
Price
1Y↑ +123.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.3M
Enterprise Value
$3.3M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$13.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
251.4%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
+86.7%
Company profile
Earnings
ESLAW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.05↓ -16.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$249,146.00 | -$1.6M | -$11.1M | -$7.3M | -$13.1M |
| Net income | -$247,718.00 | -$996,104.00 | -$11.1M | -$7.3M | -$13.1M |
| Diluted EPS | — | — | -$36.35 | -$0.27 | -$0.35 |
| Operating cash flow | -$316,158.00 | -$1.0M | -$1.3M | -$16.1M | -$1.8M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.9M | -$3.4M | -$1.1M | -$2.1M | -$5.5M | -$4.8M | -$613,199.00 | -$2.3M |
| Net income | -$4.0M | -$3.4M | -$1.1M | -$2.1M | -$5.5M | -$4.8M | -$613,174.00 | -$2.3M |
| Diluted EPS | -$0.11 | -$0.09 | -$0.03 | -$0.06 | -$0.15 | -$0.13 | -$0.01 | -$0.05 |
| Operating cash flow | -$291,513.00 | -$2.2M | -$896,066.00 | -$465,981.00 | -$414,879.00 | -$727,332.00 | -$177,487.00 | -$6.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Coming soonHeadlines for ESLAW will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-07 | Xu Jiandong· Chief Financial Officer | Buy | 1,000 | $1.33 | $1,330.00 | filing |
| 2025-09-22 | Xu Jiandong· Chief Financial Officer | Buy | 1,000 | $1.16 | $1,160.00 | filing |
| 2025-09-11 | Xu Jiandong· Chief Financial Officer | Buy | 100 | $1.04 | $104.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.